ex
vivo
celltissuebas
model
essenti
step
workflow
pathophysiolog
studi
assay
develop
diseas
model
drug
discoveri
develop
person
therapeut
strategi
purpos
scientif
pharmaceut
research
adopt
ex
vivo
stem
cell
model
better
predict
power
matter
fact
advanc
isol
vitro
expans
protocol
cultur
autolog
human
stem
cell
standard
method
gener
patientderiv
induc
pluripot
stem
cell
made
feasibl
gener
investig
human
cellular
diseas
model
even
greater
speed
effici
furthermor
potenti
stem
cell
gener
complex
system
scaffoldcel
model
organoid
organonachip
allow
overcom
limit
twodimension
cultur
system
well
better
mimic
tissu
structur
function
final
advent
genomeeditinggen
therapi
technolog
great
impact
gener
profici
stem
celldiseas
model
establish
effect
therapeut
treatment
review
discuss
import
breakthrough
stem
cellbas
model
highlight
current
direct
advantag
limit
point
need
combin
experiment
biolog
comput
tool
abl
describ
complex
biolog
system
deliv
result
predict
context
person
medicin
past
decad
much
understand
human
physiolog
patholog
deriv
studi
anim
model
howev
year
emerg
limit
rais
doubt
reliabl
investig
approach
main
critic
actual
predict
valu
anim
model
relat
limit
fulli
recapitul
human
physiologypatholog
eg
differ
pharmacokinet
toxicokinet
presenc
altern
pathway
may
interfer
progress
given
diseas
differ
immunerespons
ii
mainten
cost
iii
ethic
issu
associ
use
thu
even
anim
model
especi
mammal
still
essenti
tool
novel
therapeut
strategi
enter
clinic
trial
use
sever
restrict
order
overcom
limit
scientist
focus
find
altern
approach
tool
could
recapitul
homeostasi
cellstissu
well
patholog
alter
therefor
vitro
celltissu
model
today
becam
promis
tool
investig
human
develop
physiolog
diseas
pathogenesi
review
progress
made
establish
profici
celltissu
model
basic
cell
cultur
system
innov
organoid
platform
sinc
establish
cell
cultur
proven
first
power
tool
vitro
investig
cell
biolog
basic
research
complex
translat
approach
classic
twodimension
cultur
usual
consist
uniqu
type
cell
primari
continu
cultur
grow
tissu
cultur
polystyren
adher
monolay
float
suspens
cultur
media
provid
essenti
nutrient
growth
factor
wide
use
obtain
larg
number
cell
thu
allow
vitro
studi
molecular
mechan
develop
metabol
assay
howev
due
inabl
recreat
vivo
complex
biolog
environ
suitabl
accur
diseas
model
limit
overcom
develop
threedimension
cell
cultur
system
rational
design
cultur
harvest
cell
microstructur
resembl
tissu
organ
shape
organ
thu
allow
better
celltocellcellenviron
contact
signal
crosstalk
essenti
event
tissu
correct
develop
function
cultur
strategi
articul
mani
differ
method
techniqu
group
scaffoldbas
nonscaffold
base
platform
particular
advantag
disadvantag
make
use
differ
applic
cultur
strategi
support
silico
model
multicellular
system
requir
sophist
techniqu
go
beyond
standard
model
formal
system
biolog
allow
complic
geometr
construct
regard
mani
comput
tool
allow
predict
profici
cell
model
method
enabl
formul
compartment
spatial
model
either
theoreticallyor
experimentallyderiv
sever
model
environ
develop
order
simul
incorpor
cellbas
model
describ
interact
dynam
cellbound
variabl
defin
molecular
speci
reactiondiffus
system
comput
tool
allow
simul
wide
rang
cellular
phenomena
space
time
determinist
stochast
tabl
abovement
techniqu
develop
respond
compel
need
find
better
preclin
model
studi
model
diseas
pathogenesi
biospic
biolog
simul
softwar
intraand
intercellular
evalu
model
simul
spatiotempor
process
live
cell
current
stem
cell
sc
diseas
model
repres
power
tool
better
understand
human
diseas
pathogenesi
develop
new
therapi
matter
fact
translat
stem
cell
intrins
properti
ie
selfrenew
plurimultipot
vitro
system
allow
gener
select
cell
lineag
involv
pathogenesi
specif
diseas
along
promot
drug
discoveri
molecular
screen
transplant
therapi
first
discoveri
sc
date
back
almost
forti
year
evan
kaufman
isol
pluripot
cell
mous
embryo
establish
vitro
cultur
embryon
stem
cell
sinc
much
research
done
sc
field
today
new
stem
cellbas
diseas
model
offer
possibl
person
model
accord
patient
observ
phenotyp
obtain
stem
cell
genotyp
donor
subject
allow
studi
also
genet
complex
disord
among
stem
cell
type
use
diseas
model
purpos
adult
stem
cell
multipot
induc
pluripot
stem
cell
ipsc
permit
establish
advanc
ex
vivo
model
gener
committeddifferenti
cell
type
involv
diseas
ii
combin
biomateri
gener
biohybrid
system
tissu
engin
applic
iii
gener
organoid
iv
gener
organsonachip
system
figur
furthermor
genom
edit
gene
therapi
biotechnolog
auxiliari
tool
achiev
gener
profici
stem
cell
diseas
model
figur
advent
ipsc
open
wide
rang
new
stem
cell
applic
wellknown
ipsc
deriv
differenti
somat
cell
fibroblast
introduc
defin
transcript
factor
accord
yamanaka
takahashi
protocol
like
pluripot
stem
cell
wide
differenti
abil
give
rise
cell
deriv
three
germ
layer
matter
fact
vitro
gener
ipsc
somat
cell
made
feasibl
molecular
studi
differ
type
diseas
neurodegen
diseas
cardiac
diseas
see
list
tabl
difficult
obtain
tissu
biopsi
autolog
stem
cell
exampl
israel
et
al
gener
ipsc
sporad
alzheim
diseas
patient
demonstr
high
level
tau
protein
hyperphosphoryl
repres
suitabl
model
studi
correl
phosphoryl
tau
activ
process
app
activ
ipsc
also
use
studi
neuron
differenti
neurodegener
famili
form
amyotroph
later
sclerosi
well
studi
effect
gene
triplic
parkinson
diseas
patient
togeth
identif
therapeut
compound
accumul
advent
ipsc
open
wide
rang
new
stem
cell
applic
wellknown
ipsc
deriv
differenti
somat
cell
fibroblast
introduc
defin
transcript
factor
accord
yamanaka
takahashi
protocol
like
pluripot
stem
cell
wide
differenti
abil
give
rise
cell
deriv
three
germ
layer
matter
fact
vitro
gener
ipsc
somat
cell
made
feasibl
molecular
studi
differ
type
diseas
neurodegen
diseas
cardiac
diseas
see
list
tabl
difficult
obtain
tissu
biopsi
autolog
stem
cell
exampl
israel
et
al
gener
ipsc
sporad
alzheim
diseas
patient
demonstr
high
level
tau
protein
hyperphosphoryl
repres
suitabl
model
studi
correl
phosphoryl
tau
activ
process
app
activ
ipsc
also
use
studi
neuron
differenti
neurodegener
famili
form
amyotroph
later
sclerosi
well
studi
effect
gene
triplic
parkinson
diseas
patient
togeth
identif
therapeut
compound
accumul
nevertheless
somat
cell
reprogram
gener
ipsc
acquir
seri
new
intrins
properti
might
gener
hurdl
applic
fact
addit
teratoma
format
karyotyp
abnorm
immatur
phenotyp
character
advent
ipsc
open
wide
rang
new
stem
cell
applic
ipsc
deriv
differenti
somat
cell
fibroblast
introd
transcript
factor
accord
yamanaka
takahashi
protocol
pluripot
stem
cell
wide
differenti
abil
give
rise
cell
derivativ
germ
layer
matter
fact
vitro
gener
ipsc
somat
cell
molecular
studi
differ
type
diseas
neurodegen
diseas
diseas
see
list
tabl
difficult
obtain
tissu
biopsi
au
cell
exampl
israel
et
al
gener
ipsc
sporad
alzheim
di
demonstr
high
level
tau
protein
hyperphosph
repres
suitabl
model
studi
correl
phosphoryl
tau
process
app
activ
ipsc
bee
studi
neuron
differenti
neurodegener
famili
form
later
sclerosi
well
studi
effect
gene
triplic
diseas
patient
togeth
identif
therapeut
compound
again
accumul
nevertheless
somat
cell
reprogram
gener
ipsc
acqu
nevertheless
somat
cell
reprogram
gener
ipsc
acquir
seri
new
intrins
properti
might
gener
hurdl
applic
fact
addit
teratoma
format
karyotyp
abnorm
immatur
phenotyp
character
unpredict
genet
background
variat
thu
make
less
reliabl
correspond
diseas
model
regard
genom
edit
tool
enabl
creat
isogen
control
ipsc
differ
origin
counterpart
gene
respons
diseas
despit
limit
ipsc
shown
promis
recapitul
complex
genet
disord
especi
combin
gene
edit
techniqu
tabl
list
human
ipsc
diseas
model
ref
patientderiv
fibroblast
alzheim
diseas
patientderiv
fibroblast
amyotroph
later
sclerosi
patientderiv
fibroblast
patientderiv
peripher
blood
mononuclear
cell
becker
muscular
dystrophi
patientderiv
fibroblast
cardiovascular
diseas
patientderiv
fibroblast
cockayn
syndrom
patientderiv
fibroblast
syndrom
patientderiv
fibroblast
duchenn
muscular
dystrophi
patientderiv
fibroblast
famili
dysautonomia
patientderiv
fibroblast
fragil
xassoci
tremorataxia
syndrom
patientderiv
fibroblast
gaucher
diseas
type
iii
patientderiv
fibroblast
huntington
diseas
patientderiv
fibroblast
juvenil
diabet
mellitu
patientderiv
fibroblast
leopard
syndrom
patientderiv
fibroblast
machadojoseph
diseas
patientderiv
fibroblast
leschnyhan
syndrom
patientderiv
fibroblast
parkinson
diseas
patientderiv
fibroblast
pomp
diseas
patientderiv
fibroblast
rett
syndrom
patientderiv
fibroblast
praderwilli
syndrom
patientderiv
fibroblast
schizophrenia
patientderiv
fibroblast
spinal
muscular
atrophi
patientderiv
fibroblast
timothi
syndrom
patientderiv
fibroblast
select
modif
cell
genet
inform
groundbreak
discoveri
revolution
concept
cell
model
innov
biotechnolog
togeth
previous
establish
allow
gener
patholog
cell
introduc
defin
mutat
respons
onset
diseas
genom
edit
well
restor
miss
gene
function
defect
cell
gene
therapi
figur
case
ipsc
adult
stem
cell
afterward
differenti
divers
cell
type
involv
patholog
accordingli
plausibl
abl
specif
studi
patholog
condit
individu
patient
consequ
person
therapeut
approach
ie
precis
medicin
also
support
gene
therapi
approach
gene
edit
procedur
briefli
gene
therapi
achiev
use
advanc
viral
vector
eg
lentivir
adenoassoci
adenovir
retrovir
nonvir
vector
system
eg
liposom
system
drive
therapeut
gene
host
cell
safeti
efficaci
strategi
may
evalu
engin
stem
cell
model
suitabl
treatment
valid
screen
potenti
mutat
insert
caus
integr
target
gene
host
dna
thu
even
use
anim
model
still
essenti
treatment
reach
clinic
phase
stem
cell
altern
model
enabl
test
effect
treatment
highli
effici
reproduc
fast
manner
instanc
adenosin
deaminas
activ
adascid
immunodefici
therapi
strimv
glaxosmithklin
gsk
approv
ema
adagenet
engin
hematopoiet
stem
cell
serv
basic
cell
model
valid
effect
gene
deliveri
procedur
ultim
use
therapeut
vehicl
vivo
end
metachromat
leukodystrophi
hematopoiet
stem
cell
transduc
arsa
gene
use
establish
restor
biochem
metabol
defect
also
use
vehicl
arsa
gene
patient
affect
moreov
ongo
studi
show
relev
engin
stem
cell
eg
ipsc
mesenchym
stem
cell
express
trophic
factor
treatment
neurodegen
disord
parkinson
diseas
alzheim
diseas
huntington
diseas
amyotroph
later
sclerosi
current
mani
patholog
target
gene
therapi
strategi
explor
clinic
trial
alreadi
avail
patient
obtain
approv
food
drug
administr
fda
european
medicin
agenc
ema
genom
edit
achiev
use
differ
nucleas
abl
introduc
doublestrand
break
dsb
doubl
helix
resolv
via
nonhomolog
end
join
nhej
homolog
direct
recombin
hdr
molecular
mechan
base
princip
genom
edit
method
list
first
use
last
discov
zinc
finger
nucleas
zfn
specif
base
pair
transcript
activatorlik
effector
nucleas
talen
one
base
pair
specif
cluster
regularli
interspac
short
palindrom
associ
system
singl
nucleotid
specif
first
two
approach
recogn
target
sequenc
result
proteindna
interact
system
util
rnadna
base
pair
wide
consid
promis
tool
manipul
gene
express
compar
talen
time
costeffect
much
easier
techniqu
vivo
deliveri
effect
although
show
less
specif
due
suscept
offtarget
specif
engin
edit
dna
stem
cell
model
design
specif
guid
rna
grna
complementari
target
sequenc
extens
descript
see
refer
tabl
comput
tool
design
grna
techniqu
allow
manipul
cell
genom
creat
specif
cell
phenotyp
use
establish
accur
ex
vivo
cell
diseas
model
well
correct
dna
mutat
link
patholog
combin
gene
therapi
procedur
tissu
engin
appli
concept
engin
biolog
develop
scaffoldbas
system
aim
reproduc
structur
physiolog
function
healthi
tissu
use
stem
cell
biomateri
allow
gener
ad
hoc
biohybrid
system
repres
tissu
either
diseas
model
figur
valid
therapeut
transplant
scaffoldbas
platform
reli
mechanobiolog
concept
biomateri
provid
nativ
tissu
chemicalphys
properti
abl
specif
steer
stem
cell
toward
tissuespecif
phenotyp
matter
fact
modul
physic
chemic
properti
biomateri
architectur
shape
mechan
properti
surfac
structur
show
control
biolog
respons
stem
cell
stem
differenti
properti
mani
type
natur
synthet
biomateri
polym
ceram
bioglass
composit
seldom
metal
combin
differ
type
stem
cell
order
faith
recapitul
key
environment
signal
thu
allow
finer
celltissu
model
elucid
complex
biolog
phenomena
stem
cell
reprogram
pathway
determin
process
date
tissu
engin
strategi
alreadi
reach
market
use
person
therapi
tabl
exampl
mani
type
skin
substitut
acellular
cellular
current
avail
treatment
wound
cryopreserv
placent
membran
human
fibroblastsderiv
substitut
hfd
approv
therapi
diabet
foot
ulcer
tabl
moreov
autolog
cartilag
cell
use
phase
iii
clinic
trial
treatment
articular
cartilag
defect
tabl
among
mani
scaffold
fabric
method
recent
receiv
great
deal
attent
one
best
tool
obtain
specif
precis
architectur
biochem
composit
biocompat
materi
support
compon
techniqu
could
possibl
faith
recreat
nativ
tissu
cellular
composit
vasculatur
architectur
vitro
thu
make
biomimet
tissu
model
could
use
studi
diseas
mechan
drug
screen
clinic
applic
accordingli
use
gener
vitro
diseas
model
tumor
microenviron
ovarian
cancer
drug
test
even
though
bioprint
tissu
organ
gave
new
possibl
tissu
engin
regen
medicin
translat
applic
still
face
challeng
matter
fact
current
obstacl
method
poor
scalabl
improv
bioink
appropri
biolog
mechan
properti
suitabl
differ
cell
type
absenc
vascular
caus
hurdl
nutrient
suppli
regulatori
aspect
nevertheless
research
technolog
advanc
limit
overcom
recent
year
progress
cell
cultur
led
product
new
system
great
potenti
cell
model
platform
figur
model
call
organoid
abil
resembl
organ
character
ii
differ
type
cell
normal
present
organ
model
iii
function
featur
organ
iv
selforgan
selforgan
inde
import
characterist
organoid
opportun
cultur
condit
appropri
nutrient
growth
factor
primari
cell
isol
biopsi
embryon
adult
stem
cell
patientderiv
ipsc
go
toward
differenti
develop
mini
organ
accord
intrins
development
pattern
thu
gener
faith
replica
tissu
morpholog
organ
therefor
organoid
hold
great
promis
ex
vivo
cell
model
power
tool
development
studi
person
medicin
accordingli
organoid
repres
major
improv
diseas
model
compar
anim
model
overcom
ethic
issu
costeffect
allow
faster
analysi
sinc
develop
first
intestin
organoid
sato
collabor
mani
model
variou
tissu
develop
follow
divers
approach
matrigel
scaffoldbas
ii
embryoid
bodi
eb
base
iii
airliquid
interfac
ali
method
use
model
great
rang
patholog
viral
infect
solid
cancer
cystic
fibrosi
endometriosi
tabl
even
last
decad
effort
made
improv
organoid
fidel
vivo
counterpart
still
sever
critic
aspect
taken
account
evalu
organoid
predict
particular
poor
control
shape
size
cell
appropri
organ
caus
hurdl
term
scalabl
highthroughput
approach
variabl
mainli
aris
lack
nutrient
suppli
due
absenc
physiolog
vascular
caus
inner
part
organoid
suffer
metabol
stress
go
toward
incorrect
differenti
death
although
limit
slow
organoid
clinic
applic
still
consid
one
best
option
current
avail
build
strong
cell
model
capabl
summar
key
featur
mani
diseas
retina
leber
congenit
amaurosi
patientderiv
ipsc
stomach
gastric
cancer
patient
tumor
biopsi
gastric
diseas
due
helicobact
pylori
infect
gastricesophag
tumor
biopsi
commerci
psc
recent
advanc
stem
cell
biolog
engin
innov
applic
microfluid
techniqu
develop
organonachip
platform
ooc
figur
rational
introduct
microfluid
cell
cultur
reproduc
microenviron
cell
use
precis
control
fluid
flow
biochem
factor
mechan
forc
aim
ooc
reproduc
vitro
function
unit
organ
reproduc
essenti
element
allow
physiolog
function
achiev
use
microfabr
cell
cultur
devic
design
replic
fundament
architectur
characterist
organ
exam
incorpor
microchamb
microchannel
allow
growth
divers
cell
type
defin
cultur
condit
thank
capillari
control
fluid
flow
moreov
tailormad
architectur
organ
ooc
enabl
studi
interact
differ
biolog
compart
cell
extracellular
matrix
ecm
tissuetissu
interfac
parenchymalvascular
associ
one
import
aspect
ooc
possibl
combin
differ
biomateri
microfabr
techniqu
extens
review
cell
type
creat
multicompart
multiphysiolog
system
model
tissu
pathophysiolog
system
develop
reflect
individu
pathophysiolog
condit
includ
blood
sampl
patientderiv
primari
adult
stem
cell
ipsc
adjust
physiochem
paramet
flow
accord
person
health
data
figur
person
strategi
could
thu
new
frontier
build
tailor
cell
diseas
model
abl
take
account
individu
patholog
variabl
way
person
treatment
possibl
har
stem
cell
versatil
differenti
cell
specif
properti
microfluid
control
allow
build
diseas
model
unpreced
featur
made
possibl
reproduc
vitro
complex
biolog
structur
could
obtain
previou
cell
cultur
technolog
bloodbrain
barrier
tabl
matter
fact
past
five
year
mani
diseas
model
develop
lungonachip
cancer
coupledooc
liver
pancrea
spheroid
abl
maintain
glucos
homeostasi
model
type
diabet
tabl
note
differ
ooc
model
link
build
ideal
humanonachip
could
theoret
serv
ultim
altern
anim
model
capac
predict
multiorgan
biolog
interact
respons
therapeut
treatment
spite
mani
advantag
ooc
reli
abil
scientist
artifici
reconstruct
correct
microenviron
use
correct
cell
type
arrang
would
physiolog
state
therefor
futur
perspect
cell
model
involv
synerg
combin
ooc
organoid
possibl
precis
control
microenvironment
condit
exploit
organoid
selforgan
aim
obtain
best
ex
vivo
cell
model
technolog
review
document
signific
improv
diseas
model
use
human
adult
stem
cell
ipsc
highlight
contribut
gener
elabor
organoid
organonachip
biohybrid
system
greatli
facilit
understand
abil
treat
human
diseas
noteworthi
also
point
tremend
advanc
field
highlight
need
model
accur
effici
safe
order
accomplish
valid
differenti
protocol
develop
effect
therapi
regard
comput
tool
abl
predict
complex
biolog
system
togeth
genom
edit
gene
therapi
technolog
support
research
develop
profici
diseas
model
collect
issu
discuss
emphas
ex
vivostem
cell
model
altern
complementari
system
anim
diseas
model
